Trial Profile
Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolterodine/pilocarpine (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors SK Chemicals
- 22 Apr 2019 Primary endpoint (ADR Incidence of Dry) has been met, according to the results published in the Journal of Urology
- 22 Apr 2019 Results published in the Journal of Urology
- 11 Jan 2017 Status changed from recruiting to completed.